Molecular replacement in cancer therapy: Reversing cancer metabolic and mitochondrial dysfunction, fatigue and the adverse effects of cancer therapy

Current Cancer Therapy Reviews

Volumn 4, Issue 1, 2008, Pages 66-76

  Conklin, Kenneth A ^a   Nicolson, Garth L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Institute for Molecular Medicine   (United States)

Author keywords

Alkylating agents; Anthracyclines; Antioxidants; Coenzyme Q10; Electron transport chain; Lipid peroxidation; Lipid replacement; Mitochondria; Oxidative stress

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CAMPTOTHECIN DERIVATIVE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; EPIRUBICIN; ETOPOSIDE; FOLIC ACID ANTAGONIST; IRINOTECAN; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE; TENIPOSIDE; TOPOTECAN; UBIDECARENONE; UNINDEXED DRUG; VINBLASTINE; VINBLASTINE SULFATE; VINCA ALKALOID; VINCRISTINE; VINCRISTINE SULFATE;

ANTINEOPLASTIC ACTIVITY; CANCER FATIGUE; CANCER THERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CELL DAMAGE; CELL FUNCTION; CELL PROTECTION; CELL STRUCTURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG STRUCTURE; ELECTROCARDIOGRAM; ELECTRON TRANSPORT; FATIGUE; HEART INJURY; HEART MUSCLE CONDUCTION DISTURBANCE; HEMATOLOGIC MALIGNANCY; HUMAN; LIPID PEROXIDATION; MALAISE; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; NAUSEA; NONHUMAN; NUTRITIONAL SUPPORT; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TISSUE INJURY; VOMITING;

EID: 49349086182     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339408783565484     Document Type: Review

References (129)

1. Betteridge DJ. What is oxidative stress? Metabolism 2000; 49(suppl 1): 3-8.
2. Kehrer JP. Free radicals and mediators of tissue injury and disease. Crit Rev Toxicol 1993; 23: 21-48.
3. Halliwell B. Oxidative stress, nutrition and health. Free Rad Res 1996; 25: 57-74.
4. Cerutti PA. Prooxidant status and tumor promotion. Science 1985; 227: 375-381.
5. Dreher D, Junod AF. Role of oxygen free radicals in cancer development. Eur J Cancer 1996; 32A: 30-38.
6. Abidi S, Ali A. Role of oxygen free radicals in the pathogenesis and etiology of cancer. Cancer Lett 1999; 142: 1-9.
7. van Ginkel G, Sevanian A. Lipid peroxidation -induced membrane structural alterations. Methods Enzymol 1994; 233: 273-288.
8. Stadtman E. Introduction to serial reviews on oxidatively modified proteins in aging and disease. Free Rad Biol Med 2002; 32: 789.
9. Hsie AW, Recio I, Katz DS, Lee CQ, Wagner M, Schenley RL. Evidence for reactive oxygen species inducing mutations in mammalian cells. Proc Natl Acad Sci USA 1986; 83: 9616-9620.
10. Marnett LJ. Oxyradicals and DNA damage. Carcinogenesis 2000; 21: 361-370.
11. Bartsch H, Nair J. Oxidative stress and lipid peroxidation -driven DNA-lesions in inflammation driven carcinogenesis. Cancer Detect Prev 2004; 28: 385-391.
12. Castro L, Freeman BA. Reactive oxygen species in human health and disease. Nutrition 2001; 17: 295-307.
13. Johnson TM, Yu ZX, Ferrans VJ, Lowenstein RA, Finkel T. Reactive oxygen species are downstream mediators of p53 -dependent apoptosis. Proc Natl Acad Sci USA 1996; 93: 11848-11852.
14. Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 2004; 44: 239-267.
15. Barber DA, Harris SR. Oxygen free radicals and antioxidants: a review. Am Pharm 1994; 34: 26-35.
16. Sun Y. Free radicals, antioxidant enzymes and carcinogenesis. Free Rad Biol Med 1990; 8: 583-599.
17. Fridovich I. Superoxide radical and superoxide dismutases. Annu Rev Biochem 1995; 64: 97-112.
18. Seifried HE, McDonald SS, Anderson DE, Greenwald P, Milner JA. The antioxidant conundrum in cancer. Cancer Res 2003; 61: 4295-4298.
19. Jagetia GC, Rajanikant GK, Rao SK, Baliga MS. Alteration in the glutathione, glutathione peroxidase, superoxide dismutase and lipid peroxidation by ascorbic acid in the skin of mice exposed to fractionated gamma radiation. Clin Chim Acta 2003; 332: 111-121.
20. Schwartz JL. The dual roles of nutrients as antioxidants and prooxidants: their effects on tumor cell growth. J Nutr 1996; 126: 1221S-1227S.
21. Aeschbach R, Loliger J, Scott BC, et al. Antioxidant actions of thymol, carvacrol, 6-gingerol, zingerone and hydroxytyrosol. Food Chem Toxicol 1994; 32: 31-36.
22. Tanaka T. Cancer chemoprevention by natural products. Oncol Rep 1994; 1: 1139-1155.
23. Prasad KN, Cole WC, Kumar B, Prasad KC. Scientific rationale for using high -dose multiple micronutrients as an adjunct to standard and experimental cancer therapies. J Am Coll Nutr 2001; 20: 450S-453S.
24. Toyokuni S, Okamoto K, Yodio J, Hiai H. Persistent oxidative stress in cancer. FEBS Lett 1995; 358: 1-3.
25. Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 2004; 44: 239-267.
26. Brown NS, Bicknell R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 2001; 3: 323-327.
27. Ray G, Batra S, Shukla NK, et al. Lipid peroxidation, free radical production and antioxidant status in breast cancer. Breast Cancer Res Treat 2000; 59: 163-170.
28. Kline K, Yu W, Sanders BG. Vitamin E and breast cancer. J Nutr 2004; 134(Suppl 12): 3458S-3462S.
29. Tas F, Hansel H, Belce A, et al. Oxidative stress in breast cancer. Med Oncol 2005; 22: 11-15.
30. Asal NR, Risser DR, Kadamani S, Geyer JR, Lee ET, Cheng N. Risk factors in renal cell carcinoma. I. Methodology, demographics, tobacco beverage use and obesity. Cancer Detect Prev 1988; 11: 359-377.
31. Gago-Dominguez M, Castelao JE, Yuan JM, Ross RK, Yu MC. Lipid peroxidation: a novel and unifying concept of the etiology of renal cell carcinoma. Cancer Causes Control 2002; 13: 287-293.
32. Sikka SC. Role of oxidative stress response elements and antioxidants in prostate cancer pathobiology and chemoprevention - a mechanistic approach. Curr Med Chem 2003; 10: 2679-2692.
33. Aydin A, Arsova-Sarafinovska Z, Sayal A, et al. Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostate hyperplasia. Clin Biochem 2006; 39: 176-179.
34. Otamiri T, Sjodahl R. Increased lipid peroxidation in malignant tissues of patients with colorectal cancer. Cancer 1989; 64: 422-425.
35. Oxdemirler G, Pabucçoglu H, Bulut T, Bugra D, Uysal M, Toker G. Increased lipoperoxide levels and antioxidant system in colorectal cancer. J Cancer Res Clin Oncol 1989; 124: 555-559.
36. Manoharan S, Kolanjiappan K, Suresh K, Panjamurthy K. Lipid peroxidation and antioxidants status in patients with oral squamous cell carcinoma. Ind J Med Res 2005; 122: 529-534.
37. Seril DN, Liao J, Yang GY, Yang CS. Oxidative stress and ulcerative colitis -associated carcinogenesis: studies in humans and animal models. Carcinogenesis 2003; 34: 353-362.
38. Batcioglu K, Mehmet N, Ozturk IC, et al. Lipid peroxidation and antioxidant status in stomach cancer. Cancer Investig 2006; 24: 18-21.
39. Jaruga P, Zastawny TH, Skokowski J, Dizdaroglu M, Olinksi R. Oxidative DNA base damage and antioxidant enzyme activities in human lung cancer. FEBS Lett 1992; 341: 59-64.
40. Demple B, Harrison L. Repair of oxidative damage to DNA: enzymology and biology. Annu Rev Biochem 1994; 63: 915-948.
41. Conklin KA. Chemotherapy -associated oxidative stress: impact on chemotherapeutic effectiveness. Intgr Cancer Ther 2004; 3: 294-300.
42. Conklin KA. Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer 2000; 37: 1-18.
43. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenals, malonaldehyde and related aldehydes. Free Radic Biol Med 1991; 11: 81-128.
44. Dianzani MU. Lipid peroxidation and cancer. Crit Rev Oncol Hematol 1993; 15: 125-147.
45. Hauptlorenz S, Esterbauer H, Moll W, Pumpel R, Schauenstein E, Puschendorf B. Effects of the lipidperoxidation product 4 - hydroxynonenal and related aldehydes on proliferation and viability of cultured Ehrlich ascites tumor cells. Biochem Pharmacol 1985; 34: 3803-3809.
46. Gonzalez MJ. Lipid peroxidation and tumor growth: an inverse relationship. Med Hypotheses 1992; 38: 106-110.
47. Schackelford RE, Kaufmann WK, Paules RS. Oxidative stress and cell cycle checkpoint function. Free Radic Biol Med 2000; 28: 1387-1404.
48. Balin AK, Goodman DBP, Rasmussen H, Cristofalo VJ. Oxygensensitive stages of the cell cycle of human diploid cells. J Cell Biol 1978; 78: 390-400.
49. Kurata S. Selective activation of p38 MAPK cascade and mitotic arrest caused by low level oxidative stress. J Biol Chem 2000; 275: 23413-23416.
50. Wei Q, Frazier ML, Levin B. DNA repair: a double edge sword. J Natl Can Inst 2000; 92: 440-441.
51. Fojo T. Cancer, DNA repair mechanisms, and resistance to chemotherapy. J Natl Can Inst 2001; 93: 1434-1436.
52. Zhen W, Link CJ, O'Connor PM, et al. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol 1992; 12: 3689-3698.
53. Chandra J, Samali A, Orrenius S. Triggering and modulation of apoptosis by oxidative stress. Free Rad Biol Med 2000; 29: 323-333.
54. Hampton MB, Orrenius S. Dual regulation of caspase activity by hydrogen peroxide: implications for apoptosis. FEBS Lett 1997; 414: 552-556.
55. Hampton MB, Fadeel B, Orrenius S. Redox regulation of the caspases during apoptosis. Ann N Y Acad Sci 1998; 854: 328-335.
56. Shacter E, Williams JA, Hinson RM, Senturker S, Lee Y -J. Oxidative stress interferes with cancer chemotherapy: inhibition of lymphoma cell apoptosis and phagocytosis. Blood 2000; 96: 307-313.
57. Lee Y -J, Shacter E. Oxidative stress inhibits apoptosis in human lymphoma cells. J Biol Chem 1999; 274: 19792-19798.
58. Conklin KA. Coenzyme Q10 for prevention of anthracycline - induced cardiotoxicity. Intgr Cancer Ther 2005; 4: 110-130.
59. Rasmussen UF, Rasmussen HN. The NADH oxidase system (external) of muscle mitochondria and its role in the oxidation of cytoplasmic NADH. Biochem J 1985; 229: 632-641.
60. Nohl H. Demonstration of the existence of an organo-specific NADH dehydrogenase in heart mitochondria. Eur J Biochem 1987; 169: 585-591.
61. Lehninger AL. Phosphorylation coupled to oxidation of dihydrodiphosphopyridine nucleotide. J Biol Chem 1951; 190: 345-359.
62. Davies KJA, Doroshow JH. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem 1986; 261: 3060-3067.
63. Doroshow JH, Davies KJA. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J Biol Chem 1986; 261: 3068-3074.
64. Nohl H. Identification of the site of Adriamycin-activation in the heart cell. Biochem Pharmacol 1988; 37: 2633-2637.
65. Gille L, Nohl H. Analyses of the molecular mechanism of Adriamycin-induced cardiotoxicity. Free Radic Biol Med 1997; 23: 775-782.
66. Eaton S, Skinner R, Hale JP, et al. Plasma coenzyme Q10 in children and adolescents undergoing doxorubicin therapy. Clin Chim Acta 2000; 302: 1-9.
67. Karlsson J, Folkers K, Astrom H, et al. Effect of Adriamycin on heart and skeletal muscle coenzyme Q10 (CoQ10) in man. In: Folkers K, Yamamura Y eds, Biomedical and Clinical Aspects of Coenzyme Q, Volume 5. Amsterdam: Elsevier/North -Holland Biomedical Press, 1986; 241-245.
68. Palmeira CM, Serrano J, Kuehl DW, Wallace KB. Preferential oxidation of cardiac mitochondrial DNA following acute intoxication with doxorubicin. Biochim Biophys Acta 1997; 1321: 101-106.
69. Serrano J, Palmeira CM, Kuehl DW, Wallace KB. Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration. Biochim Biophys Acta 1999; 1411: 201-205.
70. Papadopoulou LC, Tsiftsoglou AS. Effects of hemin on apoptosis, suppression of cytochrome C oxidase gene expression, and bone - marrow toxicity induced by doxorubicin. Biochem Pharmacol 1996; 52: 713-722.
71. Domae N, Sawada H, Matsuyama E, Konishi T, Uchino H. Cardiomyopathy and other chronic toxic effects induced in rabbits by doxorubicin and possible prevention by coenzyme Q10. Cancer Treat Rep 1981; 65: 79-91.
72. Sawada H, Dohmae N, Tashima M, et al. Chronic cardiotoxicity of Adriamycin and possible prevention by coenzyme Q10 in rabbits. Biomedical and Clinical Aspects of Coenzyme Q, In Yamamura Y, Folkers K, Ito Y, ed. Amsterdam: Elsevier/North - Holland Biomedical Press, 1980; Vol. 2, 189-204.
73. Usui T, Ishikura H, Izumi Y, et al. Possible prevention from the progression of cardiotoxicity in Adriamycin -treated rabbits by coenzyme Q10. Toxicol Lett 1982; 12: 75-82.
74. Ghione M, Bertazzoli C. Co Q and anthracycline associated cardiomyopathy. In Biomedical and Clinical Aspects of Coenzyme Q, ed. Folkers K, Yamamura Y, Amsterdam: Elsevier/North - Holland Biomedical Press 1977; 183 -199.
75. Yamanaka N, Kato T, Nishida K, Fujikawa T, Fukushima M, Ota K. Protective effect of coenzyme Q10 on Adriamycin toxicity and increase of antitumor effects of Adriamycin by coenzyme Q10. In: Biomedical and Clinical Aspects of Coenzyme Q, ed. Yamamura Y, Folkers K, Ito Y, Amsterdam: Elsevier/North-Holland Biomedical Press 1980; Vol. 2, 213-224.
76. Judy WV, Hall JH, Dugan W, Toth PD, Folkers K. Coenzyme Q10 reduction of Adriamycin cardiotoxicity. In: Biomedical and Clinical Aspects of Coenzyme Q, ed. Folkers K, Yamamura Y, Amsterdam: Elsevier/North -Holland Biomedical Press, 1984; Vol. 4, 231-241.
77. Cortes EP, Gupta M, Chou C, Amin VC, Folkers, K. Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10. Cancer Treat Rep 1978; 62: 887-891.
78. Cortes EP, Gupta M, Chou C, Patel M, Mundia A, Folkers K. Study of administration of coenzyme Q10 to Adriamycin treated cancer patients. In Biomedical and Clinical Aspects of Coenzyme Q, ed. Folkers K, Yamamura Y, Amsterdam: Elsevier/North -Holland Biomedical Press, 1977; 267-278.
79. Iarussi D, Auricchio U, Agretto A, et al. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non -Hodgkin lymphoma. Mol Aspects Med 1994; 15: S207-S212.
80. Folkers K, Baker L, Richardson PC, et al. Biomedical and clinical research on coenzyme Q10. In Biomedical and Clinical Aspects of Coenzyme Q, ed. Yamamura Y, Folkers K, Ito Y, Amsterdam: Elsevier/North -Holland Biomedical Press 1980; Vol. 2, 447-454.
81. Folkers K, Baker L, Richardson PC, et al. New progress on the biomedical and clinical research on coenzyme Q10. In Biomedical and Clinical Aspects of Coenzyme Q, ed. Folkers K, Yamamura Y, Amsterdam: Elsevier/North -Holland Biomedical Press, 1981; Vol. 3, 399-412.
82. Okuma K, Ota K. The effect of coenzyme Q10 on ECG changes induced by doxorubicin (Adriamycin). In, Biomedical and Clinical Aspects of Coenzyme Q, ed. Folkers K, Yamamura Y, Amsterdam: Elsevier/North-Holland Biomedical Press, 1986; Vol. 5, 247-256.
83. Takimoto M, Sakurai T, Kodama K, et al. Protective effect of CoQ 10 administration on cardial toxicity in FAC therapy. Gan To Kagaku Ryoho 1982; 9: 116-121.
84. Tsubaki K, Horiuchi A, Kitani T, et al. Investigation of the preventive effect of CoQ10 against the side-effects of anthracycline antineoplastic agents. Gan To Kagaku Ryoho 1984; 11: 1420-1427.
85. Yamamura Y. A survey of the therapeutic uses of coenzyme Q. In Coenzyme Q. Biochemistry, Bioenergetics and Clinical Applications of Ubiquinone, ed. Lenaz G, Chichester: John Wiley & Sons, 1985; 479-505.
86. Buckingham R, Fitt J, Sitzia J. Patients' experience of chemotherapy: side -effects of carboplatin in the treatment of carcinoma of the ovary. Eur J Cancer Care 1997; 6: 59-71.
87. Loke YK, Price D, Derry S, Aronson JK. Case reports of suspected adverse drug reactions-systematic literature survey of follow -up. Br Med J 2006; 232: 335-339.
88. Vogelzang N, Breitbart W, Cella D, et al. Patient caregiver and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. Semin Hematol 1997; 34(Suppl 2): 4-12.
89. Romanelli A, Bozzone A, Magrone G, et al. Cancer-related fatigue: evaluation and treatment. Rays 2004; 29: 453-455.
90. Bender CM, Ergyn FS, Rosenzweig MQ, et al. Symptom clusters in breast cancer across three phases of the disease. Cancer Nurs 2005; 28: 219-225.
91. Ahlberg K, Ekman T, Gaston -Johansson F. Fatigue, psychological distress, coping resources, and functional status during radiotherapy for uterine cancer. Oncol Nurs Forum 2005; 32: 633-640.
92. Shafqat A, Einhorn LH, Hanna N, et al. Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment. Ann Oncol 2005; 16: 1545-1550.
93. Liu L, Marler MR, Parker BA, et al. The relationship between fatigue and light exposure during chemotherapy. Support Care Cancer 2005; 13: 1010-1017.
94. Von Roenn JH, Paice JA. Control of common, non-pain cancer symptoms. Semin Oncol 2005; 32: 200-210.
95. Nicolson GL. Lipid replacement/antioxidant therapy as an adjunct supplement to reduce the adverse effects of cancer therapy and restore mitochondrial function. Pathol Oncol Res 2005; 11: 139-144.
96. Kroenke K, Wood DR, Mangelsdorff AD, et al. Chronic fatigue in primary care. Prevalence, patient characteristics, and outcome. JAMA 1988; 260: 929-934.
97. Morrison JD. Fatigue as a presenting complaint in family practice. J Family Pract 1980; 10: 795-801.
98. McDonald E, David AS, Pelosi AJ, Mann AH. Chronic fatigue in primary care attendees. Psychol Med 1993; 23: 987-998.
99. Piper BF, Linsey AM, Dodd MJ. Fatigue mechanism in cancer. Oncol Nursing Forum 1987; 14: 17-23.
100. Piper BF, Dribble SL, Dodd MJ, et al. The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. Oncol Nursing Forum 1998; 25: 667-684.
101. Nicolson GL. Lipid replacement as an adjunct to therapy for chronic fatigue, anti -aging and restoration of mitochondrial function. J Am Nutraceut Assoc 2003; 6(3): 22-28.
102. Huang H, Manton KG. The role of oxidative damage in mitochondria during aging: a review. Front Biosci 2004; 9: 1100-1117.
103. Richter C, Par JW, Ames B. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc Nat Acad Sci USA 1998; 85: 6465-6467.
104. Wei YH, Lee HC. Oxidative stress, mitochondrial DNA mutation and impairment of antioxidant enzymes in aging. Exp Biol Med 2002; 227: 671-682.
105. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1956; 2: 298-300.
106. Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 2001; 18: 685-716.
107. Chen D, Cao G, Hastings T, et al. Age-dependent decline of DNA repair activity for oxidative lesions in rat brain mitochondria. J Neurochem 2002; 81: 1273-1284.
108. Xu D, Finkel T. A role for mitochondria as potential regulators of cellular life span. Biochem Biophys Res Commun 2002; 294: 245-248.
109. Logan AC, Wong C. Chronic fatigue syndrome: oxidative stress and dietary modifications. Altern Med Rev 2001; 6: 450-459.
110. Manuel Y, Keenoy B, Moorkens G, et al. Antioxidant status and lipoprotein peroxidation in chronic fatigue syndrome. Life Sci 2001; 68: 2037-2049.
111. Richards RS, Roberts TK, McGregor NR, et al. Blood parameters indicative of oxidative stress are associated with symptom expression in chronic fatigue syndrome. Redox Rep 2000; 5: 35-41.
112. Felle S, Mecocci P, Fano G, et al. Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radic Biol Med 2000; 29: 1252-1259.
113. Pall ML. Elevated, sustained peroxynitrite levels as the cause of chronic fatigue syndrome. Med Hypotheses 2000; 54: 115-125.
114. Castro L, Rodriguez M, Radi R. Aconitase is readily inactivated by peroxynitrite, but not by its precursor, nitric oxide. J Biol Chem 1994; 269: 29409-29415.
115. Radi R, Rodriguez M, Castro L, Telleri R. Inhibition of mitochondrial electronic transport by peroxynitrite. Arch Biochem Biophys 1994; 308: 89-95.
116. Kanno T, Sato EE, Muranaka S, et al. Oxidative stress underlies the mechanism for Ca(2+)-induced permeability transition of mitochondria. Free Radic Res 2004; 38: 27-35.
117. Nicolson GL, Poste G, Ji T. Dynamic aspects of cell membrane organization. Cell Surface Rev 1977; 3: 1-73.
118. Subczynski WK, Wisniewska A. Physical properties of lipid bilayer membranes: relevance to membrane biological functions. Acta Biochim Pol 2000; 47: 613-625.
119. Nicolson GL, Ellithrope R. Lipid replacement and antioxidant nutritional therapy for restoring mitochondrial function and reducing fatigue in chronic fatigue syndrome and other fatiguing illnesses. J Chronic Fatigue Syndr 2005; 13(1): 57-68.
120. Agadjanyan M, Vasilevko V, Ghochikyan A, et al. Nutritional supplement (NTFactor) restores mitochondrial function and reduces moderately severe fatigue in aged subjects. J Chronic Fatigue Syndr 2003; 11(3): 23-26.
121. Hajri T, Abumrad NA. Fatty acid transport across membranes: relevance to nutrition and metabolic pathology. Annu Rev Nutr 2002; 22: 383-415.
122. Hamilton JA. Fatty acid transport: difficult or easy? J Lipid Res 1998; 39: 467-481.
123. Fellmann P, Herve P, Pomorski T, et al. Transmembrane movement of diether phospholipids in human erythrocytes and human fibroblasts. Biochemistry 2000; 39: 4994-5003.
124. Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature 2003; 422: 37-44.
125. Mansbach CM, Dowell R. Effect of increasing lipid loads on the ability of the endoplasmic reticulum to transport lipid to the Golgi. J Lipid Res 2000; 41: 605-612.
126. Ames BM. Micronutrients prevent cancer and delay aging. Toxicol Lett 1998; 102: 1035-1038.
127. Seidman M, Khan MJ, Tang WX, Quirk WS. Influence of lecithin on mitochondrial DNA and age -related hearing loss. Otolaryngol Head Neck Surg 2002; 127: 138-144.
128. Ellithorpe RR, Settineri R, Nicolson GL. Reduction of fatigue by use of a dietary supplement containing glycophospholipids. J Am Nutraceut Assoc 2003; 6(1): 23-28.
129. Colodny L, Lynch K, Farber C, et al. Results of a study to evaluate the use of Propax to reduce adverse effects of chemotherapy. J Am Nutraceut Assoc 2000; 2(1): 17-25.